Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other Non-Current Assets: 2017-2025

Historic Other Non-Current Assets for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $18.4 million.

  • Crinetics Pharmaceuticals' Other Non-Current Assets rose 1317.85% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 1317.85%. This contributed to the annual value of $2.8 million for FY2024, which is 41.45% up from last year.
  • Crinetics Pharmaceuticals' Other Non-Current Assets amounted to $18.4 million in Q3 2025, which was up 23.39% from $14.9 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $18.4 million during Q3 2025, with a 5-year trough of $500,000 in Q1 2021.
  • Over the past 3 years, Crinetics Pharmaceuticals' median Other Non-Current Assets value was $1.3 million (recorded in 2023), while the average stood at $5.5 million.
  • In the last 5 years, Crinetics Pharmaceuticals' Other Non-Current Assets declined by 0.08% in 2024 and then spiked by 1,317.85% in 2025.
  • Quarterly analysis of 5 years shows Crinetics Pharmaceuticals' Other Non-Current Assets stood at $500,000 in 2021, then soared by 160.20% to $1.3 million in 2022, then spiked by 53.73% to $2.0 million in 2023, then surged by 41.45% to $2.8 million in 2024, then surged by 1,317.85% to $18.4 million in 2025.
  • Its Other Non-Current Assets was $18.4 million in Q3 2025, compared to $14.9 million in Q2 2025 and $14.2 million in Q1 2025.